AMCP webinar that reviewed the provisions contained in the proposed Contract Year 2021 and 2022 Medicare Advantage and Part D rule that was released by the Centers for Medicare and Medicaid Services (CMS) on February 5, 2020.
Press Release: The Trump Administration today pulled its proposed rule to eliminate safe harbor protections for rebates paid by pharmaceutical manufacturers to PBMs and health plans in Medicare and Medicaid programs.
Press Release: According to a newly released survey from AMCP, nearly 63 percent of Medicare beneficiaries say they would recommend MTM services provided under the Part D prescription drug program to friends and relatives.
On March 1, 2019, AMCP provided comments to CMS in response to its 2020 for Medicare Part D Call Letter. AMCP offered comments on the following sections of the notice; Part D Benefit Parameters for Non-Defined Standard Plans; Formulary Submissions; Medication Therapy Management (MTM); and Part D Mail Order Auto-Ship Modifications.
Press Release: AMCP CEO Susan A. Cantrell, RPh, CAE, issued the following statement on HHS’s proposed rule to eliminate negotiated rebates for pharmaceuticals under Medicare Part D and managed Medicaid programs.